2011
DOI: 10.1016/j.fertnstert.2011.04.050
|View full text |Cite
|
Sign up to set email alerts
|

Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
33
1
1

Year Published

2012
2012
2022
2022

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 40 publications
(36 citation statements)
references
References 29 publications
0
33
1
1
Order By: Relevance
“…Similarly, the use of more-aggressive luteal support after the GnRH agonist trigger, was also associated with superior reproductive outcome (50% vs. 37.8% vs. 20%, respectively) when compared with the GnRH agonist alone and standard luteal support (20,6% vs.25.3% vs.58.2%, respectively) (p<.001) with no cases of OHSS (p=.723) [11]. Since the lower pregnancy rates after the GnRH agonist trigger with peak estradiol (E2) <4,000 pg/mL and intensive luteal support were attributed to the lower LH levels on the day of trigger [23], the use of the dual trigger with GnRH agonist and low-dose hCG compared the reproductive outcome with GnRH agonist trigger alone in high responders with peak E2 <4,000 pg/mL. It appears that the dual trigger with low-dose hCG (1,000 IU) and leuprolide acetate (1 mg) combined with intensive luteal support is an effective strategy with only one case of mild OHSS and a significantly higher live birth rate (52.9% vs. 30.9%) (p=.03), implantation rate (41.9% vs. 22.1%) (p<.01) and clinical pregnancy rate (58.8% vs. 36.8%) (p=.03) compared with the GnRH agonist trigger group [12].…”
Section: Dual Triggermentioning
confidence: 99%
“…Similarly, the use of more-aggressive luteal support after the GnRH agonist trigger, was also associated with superior reproductive outcome (50% vs. 37.8% vs. 20%, respectively) when compared with the GnRH agonist alone and standard luteal support (20,6% vs.25.3% vs.58.2%, respectively) (p<.001) with no cases of OHSS (p=.723) [11]. Since the lower pregnancy rates after the GnRH agonist trigger with peak estradiol (E2) <4,000 pg/mL and intensive luteal support were attributed to the lower LH levels on the day of trigger [23], the use of the dual trigger with GnRH agonist and low-dose hCG compared the reproductive outcome with GnRH agonist trigger alone in high responders with peak E2 <4,000 pg/mL. It appears that the dual trigger with low-dose hCG (1,000 IU) and leuprolide acetate (1 mg) combined with intensive luteal support is an effective strategy with only one case of mild OHSS and a significantly higher live birth rate (52.9% vs. 30.9%) (p=.03), implantation rate (41.9% vs. 22.1%) (p<.01) and clinical pregnancy rate (58.8% vs. 36.8%) (p=.03) compared with the GnRH agonist trigger group [12].…”
Section: Dual Triggermentioning
confidence: 99%
“…However, optimal cryopreservation programs are not available worldwide, additional costs are incurred, patient satisfaction may decline and concerns are raised regarding epigenetic changes and reproductive outcomes [22]. Intense progesterone and estradiol supplementation have been proposed with conflicting results [4,16,[23][24][25][26]. Another strategy for luteal phase rescue after GnRHa triggering is adding low-dose hCG to estradiol and progesterone [27].…”
Section: Discussionmentioning
confidence: 99%
“…Araştırmacılar, bu çalış-manın sonuçlarına dayanarak; serum pik östradiol değeri <4.000 pg/mL olan hasta grubunda ovülas-yon tetikleme gününde GnRHa'ya 1.000 IU hCG eklemek ya da tetiklemeden 35 saat sonra (OPU gü-nünde) 1.500 IU hCG eklemekle daha iyi sonuçlar elde edilebileceğini belirtmişlerdir. 31 Bu konuyla ilgili aynı merkezden yapılan başka bir çalışmada, GnRH-A protokol ve GnRHa ile tetikleme yapılan 508 otolog ve donör IVF siklusu incelenmiştir. Bütün hastaların GnRHa tetikleme sonrası 8-12. saatler arasında LH, östradiol ve progesteron hormon seviyelerine bakılmıştır.…”
Section: Gnrha Teti̇kleme Sonrasi Yüksek Doz öStradi̇ol Ve Progesteron unclassified